EFFICACY AND SAFETY OF IBANDRONIC ACID ADMINISTERED INTRAVENOUSLY TO JUVENILE ARTHRITIS PATIENTS WITH SEVERE SYSTEM OSTEOPOROSIS
Abstract
The article is dedicated to study of efficacy and safety of ibandronic acid administered intravenously to 25 patients suffering from juvenile arthritis and system osteoporosis. It was concluded that administration of 3 mg of ibandronate every 3 months during 76 weeks increase CTX, which indicates improvement of bone metabolism. During the treatment no subsequent vertebrae fractures have been registered. Increase in bone mass during the ibandronate therapy has been sufficient to allow endoprosthetic hip replacement in 7 patients.
Key words: child, juvenile arthritis, osteoporosis, treatment, biophosphates, ibandronic acid.
(Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (6): 83–88)
About the Authors
R.V. DenisovaRussian Federation
E.I. Alexeeva
Russian Federation
V.G. Pinelis
Russian Federation
M.I. Bakanov
Russian Federation
S.I. Valieva
Russian Federation
T.M. Bzarova
Russian Federation
K.B. Isaeva
Russian Federation
S.Yu. Morev
Russian Federation
G.V. Kuznetsova
Russian Federation
Review
For citations:
Denisova R., Alexeeva E., Pinelis V., Bakanov M., Valieva S., Bzarova T., Isaeva K., Morev S., Kuznetsova G. EFFICACY AND SAFETY OF IBANDRONIC ACID ADMINISTERED INTRAVENOUSLY TO JUVENILE ARTHRITIS PATIENTS WITH SEVERE SYSTEM OSTEOPOROSIS. Current Pediatrics. 2011;10(6):83–88.
Email this article 
